Solian is a prescription antipsychotic containing amisulpride for adults with schizophrenia. It helps regulate dopamine signalling and may reduce hallucinations, delusions, disorganised thinking, and related symptoms when prescribed for the individual clinical situation.
Solian contains amisulpride, an atypical antipsychotic used in psychiatric care, mainly for schizophrenia and related psychotic symptoms. It is supplied as oral tablets and is taken according to an individually confirmed regimen. Schizophrenia is a long-term mental health condition involving changes in perception, thought, mood, and behaviour.
NICE guidance places antipsychotic treatment within a wider care plan that can include psychological support, physical-health monitoring, and relapse-prevention planning [1].
The medicine may help control positive symptoms such as hallucinations and delusions, while some patients also receive it for prominent negative symptoms, including reduced motivation and social withdrawal.
Antipsychotic treatment aims to reduce acute symptoms and lower the likelihood of relapse. Solian does not produce an immediate calming effect in every patient; improvement may develop gradually as treatment continues.
Amisulpride is a dopamine D2 and D3 receptor antagonist. It acts mainly within brain pathways involved in psychosis, with receptor effects that vary according to the dose prescribed and the brain region involved. This pharmacology distinguishes it from medicines that primarily block serotonin reuptake.
Solian is not suitable for everyone. A prescriber needs a complete medical history before confirming treatment.
Amisulpride can interact with medicines that affect heart rhythm, blood pressure, sedation, or dopamine signalling. Relevant examples include some antiarrhythmics, certain antibiotics, medicines used for depression, other antipsychotics, sedatives, and drugs that lower potassium. The prescriber should also know about diuretics, because electrolyte changes can increase cardiac risk.
This medicine may not be suitable if you have had an allergic reaction to amisulpride, heart-rhythm problems, abnormal potassium or magnesium levels, severe kidney problems, Parkinson’s disease, epilepsy, significant cardiovascular disease, or a prolactin-dependent tumour. Tell your prescriber about all medicines you take, especially those affecting heart rhythm, sedation, blood pressure, dopamine signalling, or potassium levels. Older adults with dementia-related psychosis require special caution, and pregnancy or breastfeeding needs an individual assessment.
Adverse effects vary between patients. The UK product information describes possible movement-related symptoms, raised prolactin, sleepiness, insomnia, anxiety, gastrointestinal symptoms, weight changes, and cardiovascular effects associated with antipsychotic treatment [2].
Common or clinically relevant effects may include:
Extrapyramidal symptoms are movement problems caused by dopamine blockade. Akathisia feels like inner agitation and an inability to sit still; it can be mistaken for worsening anxiety. Parkinsonism may involve stiffness, tremor, and slowed movement. Tardive dyskinesia can appear as repetitive movements of the mouth, tongue, face, or limbs after longer exposure.
Seek urgent medical help for:
Neuroleptic malignant syndrome is rare but life-threatening. It combines features such as fever, severe rigidity, autonomic instability, and altered mental state. The MHRA recognises antipsychotics as medicines requiring attention to movement disorders, cardiovascular risk, and other serious reactions [3].
Solian contains amisulpride as its active substance. It is an atypical antipsychotic supplied as oral tablets for adults with schizophrenia and related psychotic symptoms. The prescribed strength and regimen are confirmed individually with a healthcare professional before treatment starts.
The regimen for the chosen strength must be confirmed with a healthcare professional before starting. Do not alter the number of tablets, divide doses, or combine strengths without specific instructions.
A missed dose should be handled according to the timing of the next scheduled dose. Taking two doses together to compensate can increase adverse effects and is not a safe routine. If several doses have been missed, the treatment plan may need reassessment before regular dosing resumes.
Solian is intended for oral use. Tablets should be swallowed with water and taken at the same time each day when possible. The prescribing clinician may advise whether the dose should be taken with food, since food can influence amisulpride absorption.
Solian tablets are taken by mouth. Use the prescribed regimen consistently, without changing the timing or quantity because symptoms seem better or worse on a particular day.
Important administration points include:
Treatment may continue for months or longer when Solian is preventing relapse. The length of treatment depends on diagnosis, episode history, response, and adverse effects. Stopping treatment because symptoms have improved can remove the protection that made the improvement possible.
Solian is an oral, single-ingredient atypical antipsychotic containing amisulpride. It differs from non-drug psychological support because it acts through dopamine signalling, while psychological interventions form part of a wider care plan rather than providing an antipsychotic medicine.
Several everyday mistakes can reduce benefit or increase risk:
A relative may notice changes before the patient does. New pacing, jaw movements, marked slowing, social withdrawal, or unusual facial movements deserve a clinical review rather than silent observation.
In clinical practice, doctors usually judge Solian by functional change as well as symptom reduction. A useful response may involve fewer voices, less suspiciousness, calmer thought processes, improved sleep, or a return to ordinary activities. Family observations can help when the patient does not recognise early changes.
A psychiatrist would usually review:
Amisulpride may be helpful when dopamine-related psychotic symptoms respond to D2/D3 blockade. Its limitations include movement symptoms, prolactin elevation, possible cardiac effects, and variable benefit between individuals. No antipsychotic removes every symptom for every patient.
The WHO’s 2021 guidance on community mental health services supports person-centred treatment that combines medication with psychosocial care, physical-health support, and attention to the patient’s goals [4].
Regular sleep, moderate physical activity, consistent meals, and limited alcohol can support day-to-day stability during treatment. Cannabis, stimulants, heavy alcohol use, and prolonged sleep deprivation may worsen psychotic symptoms or impair concentration. NHS mental-health guidance in 2025 continued to support physical-health monitoring and lifestyle care alongside treatment for psychosis. Changes should be practical and sustainable rather than extreme. A clinician can help tailor these measures to the person’s symptoms and treatment plan.
Do not increase Solian yourself if hallucinations, delusions, withdrawal, or disorganised thinking continue. Contact the prescribing service for a review of adherence, timing, interactions, diagnosis, kidney function, and the possibility of a different treatment plan. The Royal College of Psychiatrists' 2025 guidance describes treatment response as something that should be assessed through symptoms and functioning, not by a single difficult day. Urgent help is needed if there is immediate danger, severe agitation, suicidal thinking, or inability to care for basic needs.
The best time depends on the prescribed regimen, sedation, insomnia, and the timing of symptoms. Some people take it at a consistent morning time, while others may be advised to take it later if drowsiness occurs. The MHRA patient-safety approach in 2024 supported individual counselling about alertness, driving, and medicine timing. Keep the chosen schedule steady unless the prescriber changes it.
Use in people under 18 requires specialist psychiatric assessment because evidence, licensed indications, developmental factors, and monitoring needs differ from adult treatment. The prescriber considers the diagnosis, severity, previous treatment, and physical-health risks before recommending amisulpride. NICE guidance from 2013 for children and young people with psychosis emphasises specialist care and careful monitoring. Do not give an adult’s Solian tablets to a child or teenager.
Pregnancy and breastfeeding require a direct risk–benefit assessment by the treating psychiatric and maternity teams. Antipsychotic exposure near delivery can produce newborn movement, feeding, breathing, or withdrawal-related symptoms, while amisulpride may raise prolactin and affect breastfeeding. The BNF 2025 pregnancy and lactation guidance supports individualised decisions rather than abrupt discontinuation. Stopping suddenly can also cause relapse, so any change should follow a planned clinical review.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Regular sleep, moderate physical activity, consistent meals, and limited alcohol can support day-to-day stability during treatment. Cannabis, stimulants, heavy alcohol use, and prolonged sleep deprivation may worsen psychotic symptoms or impair concentration. NHS mental-health guidance in 2025 continued to support physical-health monitoring and lifestyle care alongside treatment for psychosis. Changes should be practical and sustainable rather than extreme. A clinician can help tailor these measures to the person’s symptoms and treatment plan.
Solian reduced the voices and suspicious thoughts that had made work difficult. After several weeks, I was able to follow conversations more easily and return to a regular routine. The improvement felt gradual, but it was clear enough for me to notice.
I became less preoccupied with frightening ideas and slept more normally after starting Solian. My day-to-day concentration improved, and I could manage shopping and appointments without the same level of distress. It gave me a steadier baseline.
Solian helped reduce the voices, but I still had some symptoms and felt restless at times. The benefit was partial rather than complete. I discussed the restlessness with my doctor, and we reviewed whether the regimen remained suitable.
